Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Valeant


T.VRX

CEO's OPEN LETTER TO SHAREHOLDERS, SHARP RECOVERY UNDER WAY

Today, Robert Ingram and Howard Schiller, interim chairman and CEO of Valeant...

January 20, 2016

T.CWB

CEO Chris Fowler Should Resign Immediately & Unconditionally

Just for the record, I also sent an e-mail calling for Mr Chris Fowler's...

January 20, 2016

T.VRX

Valeant Pharmaceuticals Expects Sharp Recovery

Although Valeant Pharmaceuticals (VRX) listed on TSX today broke even (+0.02%...

January 19, 2016

T.CWB

Incompetent Chris Fowler, Canadian Western Bank CEO

Please E-mail CEO Chris Fowler and ask him to resign: chris.fowler...

January 19, 2016

T.CWB

chris.fowler@cwbank.com <-- ask him to resign

Please E-mail CEO of Canadian Western Bank and ask him to resign: chris...

January 16, 2016

T.CWB

CWB CEO Chris H. Fowler is incompetent, should be fired

Please E-mail CEO Chris Fowler and ask him to resign: chris.fowler@cwbank.com...

January 16, 2016

T.VRX

Linear Regression Points Upside for Valeant Pharmaceuticals

Linear Regression has 95% confidence interval in statistics and it points to...

January 16, 2016

T.CWB

CWB Price Target Increased to $35, appr. 75% upside

Canadian Western Bank (CWB)'s is a 'Buy" according to the...

January 14, 2016

T.VRX

UPDATE: VRX PRICE TARGET $195 (117.22% UPSIDE), GUGGENHEIM

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)‘s stock had its “buy” rating...

January 14, 2016